Close this search box.

We are creating some awesome events for you. Kindly bear with us.

AI Platform Optimises Chemotherapy Dose in Singapore

The concept of the use of artificial intelligence in medicine. The doctor clicks on the artificial brain.

The National University of Singapore (NUS) has reported good results in employing CURATE.AI, an artificial intelligence (AI) application that helps clinicians identify appropriate and tailored chemotherapy doses for patients. The research is in partnership with clinicians from the National University Cancer Institute, Singapore (NCIS) which is part of the National University Health System (NUHS).

The goal of CURATE.AI is to potentially uncover more treatment responders, as well as to find the best doses for patients to maximise efficacy and extend the time a patient is receptive to treatment. These doses may be lower for some patients than the high amounts that have been used in the past.

“Using CURATE.AI, which is efficacy-driven, we hope to help doctors quickly identify the optimal doses that are customised for each patient at different stages of the treatment cycle,” explained Dr Dean Ho, who heads the NUS Department of Biomedical Engineering and co-corresponding author of the study.

Dr Ho added that the goal is to improve both patient and treatment outcomes. Chemotherapy is frequently administered in fixed doses based on patient parameters. These toxicity-guided doses, however, may not result in an optimal response to treatment.

Dr Ho created the CURATE.AI together with his colleagues. He explained that the platform is an optimisation programme that uses a patient’s clinical data, including medication kind, dose, and cancer biomarkers, to create a customised digital profile that can be used to tailor the best dose during chemotherapy treatment.

The direct involvement of clinicians in building individualised datasets is an important aspect of applying AI in medicine. The pilot trial is an encouraging first step toward incorporating CURATE.AI into the clinical workflow of dynamic dose selection in the treatment of solid tumours.

The primary goal of CURATE.AI will enable truly personalised dosing for patients while also empowering clinicians to determine the best dose for each patient without increasing their workload. Clinicians can thus devote more time to the patient and caregiver.

Moreover, CURATE.AI uses each patient’s clinical data to calibrate medicine dosage. Each patient is given different pharmacological doses and their response is measured. This data is combined with clinical data to create a digital patient profile. It optimises treatment outcomes for each digital profile by linking medicine dosing to efficacy and safety. The dose may change during treatment.

Clinicians were allowed to accept or reject CURATE.AI dose recommendations based on the clinical judgement during the pilot trial, which ran from August 2020 to April 2022 at the National University Hospital.

The results of the pilot trial were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting as a prospective and interventional study that harnesses an AI-based approach to human treatment. ASCO is a leading professional organisation for cancer caregivers, and the meeting will feature presentations on the most recent advances in cancer research.

Other study findings included patient adherence to suggested doses of 80 per cent and 100 per cent compliance in delivering dosing recommendations within the appropriate timeframe. These preliminary findings are encouraging in terms of CURATE’s downstream deployment. Putting artificial intelligence into clinical practice.

Following this initial step toward incorporating CURATE.AI into clinical workflows for dose selection in solid tumour treatment, the NUS team will move forward with a larger, randomised trial to further validate the platform’s performance.

The research team will also conduct clinical trials involving patients with other types of cancer, such as multiple myeloma, as well as disorders such as hypertension. Notably, the team will soon begin a trial to optimise personalised immunotherapy dosing for solid cancers.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.